Title:
COMPOSITION COMPRISING A DOPAMINE AGONIST AND AN L-DOPA DERIVATIVE FOR TREATING PARKINSON'S DISEASE
Document Type and Number:
WIPO Patent Application WO/2015/136003
Kind Code:
A3
Abstract:
Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition is used for the treatment of Parkinson's disease, restless leg syndrome, dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormones, for the treatment of neurological symptoms of chronic manganese intoxication, oamyotrophic lateral sclerosis, and multiple system atrophy.
Inventors:
ALKEN RUDOLF-GIESBERT (SE)
SCHNEIDER FRANK (DE)
SCHNEIDER FRANK (DE)
Application Number:
PCT/EP2015/055099
Publication Date:
November 26, 2015
Filing Date:
March 11, 2015
Export Citation:
Assignee:
IMPHAR AG (DE)
International Classes:
A61K9/08; A61K31/198; A61K31/4045; A61K31/428; A61K31/506; A61P5/06; A61P25/14; A61P25/16; A61P25/26; A61P25/28
Domestic Patent References:
| WO2007093450A2 | 2007-08-23 | |||
| WO2015077520A1 | 2015-05-28 |
Other References:
MICHAEL P HILL ET AL: "Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset", MOVEMENT DISORDERS : OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY, 1 November 2003 (2003-11-01), United States, pages 1301 - 1305, XP055133641, Retrieved from the Internet DOI: 10.1002/mds.10542
BAAS H ET AL: "Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 21, no. 2, 1 March 1998 (1998-03-01), pages 86 - 92, XP008171080, ISSN: 0362-5664
GIRON L T ET AL: "METHODS OF MANAGING LEVODOPA-INDUCED DYSKINESIAS", DRUG SAFETY, ADIS PRESS, AUCKLAND, NZ, vol. 14, no. 6, 1 January 1996 (1996-01-01), pages 365 - 374, XP001087545, ISSN: 0114-5916
MALMLOF ET AL., EXP NEUROL, vol. 225, 2010, pages 408 - 415, XP027274374
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490
BAAS H ET AL: "Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations", CLINICAL NEUROPHARMACOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 21, no. 2, 1 March 1998 (1998-03-01), pages 86 - 92, XP008171080, ISSN: 0362-5664
GIRON L T ET AL: "METHODS OF MANAGING LEVODOPA-INDUCED DYSKINESIAS", DRUG SAFETY, ADIS PRESS, AUCKLAND, NZ, vol. 14, no. 6, 1 January 1996 (1996-01-01), pages 365 - 374, XP001087545, ISSN: 0114-5916
MALMLOF ET AL., EXP NEUROL, vol. 225, 2010, pages 408 - 415, XP027274374
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490
Attorney, Agent or Firm:
MÜLLER & SCHUBERT PATENTANWÄLTE (Berlin, DE)
Download PDF: